Rimini et alAhn et allenvatinibatezolizumab-bevacizumabHepatocellular carcinomaimmunotherapydurvalumabHCCtremelimumabsystemic therapies
… the comparative effectiveness of lenvatinib and immunotherapy. Rimini et al noted a survival benefit for lenvatinib in HCC, though real-wor…